Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk AS (NVO) reports strong sales and profit growth, while addressing compounding challenges and expanding its ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth ...

Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% ...